drugset / Trial / NCT05369052
Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a Phase 3, multicenter, randomized, double-blind, safety and efficacy study of contezolid acefosamil (IV)/contezolid (PO) compared with linezolid (IV and PO) administered for a total of 14 to 28 days in adult subjects with moderate or severe DFI.
Timeline
- Start
- 2022-05-03
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Contezolid | Small molecule | — | Oral |
| Comparator | Linezolid | Other / unclassified | — | Intravenous |
| Subject | contezolid acefosamil | Unknown | — | Intravenous |
Indications
No indication recorded.